Adacolumn®: Fostering Synergies, Reducing Risks

Dr. Rodríguez-Lago shares existing evidence of the crucial role played by innate immunity in the pathogenesis of Inflammatory Bowel Disease (IBD), as well as in the failure of advanced therapies such as biologic drugs and small molecules. Hence, the combined use of granulocyte and monocyte apheresis (GMA, Adacolumn®) targeting mainly innate IBD trigger cells, such as neutrophils and monocytes, with these treatments, which act mainly on lymphocytes and acquired immunity, theoretically represents a very attractive option due to their potential synergistic effects.

Dr. Rodríguez-Lago reviews the existing evidence of the use of GMA in combination with each of these treatments and shows us how, also in practice, and even using advanced techniques such as single-cell analysis, very favorable results are obtained in patients refractory to them, thus confirming this hypothesis, although larger studies are required to confirm these data.

Below, we include a short interview with Dr. Rodriguez-Lago highlighting the most important messages of the course.

Also included is the evaluation of the presented data by the moderator of the course and IBD expert, Prof. Eugeni Domènech from the University Hospital Germans Trias i Pujol from Barcelona.